2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sameer Parikh, MD, hematologist, Mayo Clinic, discusses the utilization and significance of the Chronic Lymphocytic Leukemia (CLL)-International Prognostic Index (IPI).
Sameer Parikh, MD, hematologist, Mayo Clinic, discusses the utilization and significance of the Chronic Lymphocytic Leukemia (CLL)-International Prognostic Index (IPI).
One of the most important contributions to the landscape of CLL has been the development of the CLL-IPI, Parikh explains. This combines 5 different factors, including age, clinical stage, TP53 mutation status, IGVH mutation status, and serum β2-microglobulin concentration.
The CLL-IPI allows physicians to prognosticate when patients are going to require therapy for their CLL. This is especially emphasized for all patients with CLL, specifically those who are newly diagnosed.
Related Content: